Chronic hepatitis B infection, chronic hepatitis C infection, parvovirus B19 infection
Citation Information :
Bajpai M, Verma Y, Gupta E, Reddy HV, Ballani N, Bhadoria AS. Human parvovirus B19 co-infection aggravates liver dysfunction in patients with chronic Hepatitis B infection. J Gastrointest Infect 2016; 6 (1):32-36.
Background and objectives: Human parvovirus B19 (B19) has been reported to be detected in the sera of patients with acute or chronic hepatitis. The aim of this study was to investigate the prevalence of parvovirus B19 in patients with chronic hepatitis B virus (CHB) and hepatitis C virus (CHC) infection and understand its clinical significance.
Materials and methods: Plasma samples from 40 adult chronic hepatitis patients (20 CHB and 20 CHC) and 20 healthy blood donors were investigated for antibodies to B19 (IgM and IgG both). Active viremia was confirmed in IgM positive patients by real time PCR for parvovirus B19. Results: IgG antibodies to B19 were seen in 5 (25%) CHB, 10 (50%) CHC and 10(50%) healthy controls. IgM antibodies to B19 were seen in 3 (15%) CHB, 5 (25%) CHC and 1 (5%) controls. The liver dysfunction was significantly higher in B19 co-infected CHB patients. The serum ALT levels (Median 416.0, IQR 64.0-496.6 IU/L) and AST levels (Median 325, IQR 61.00- 380.00 IU/L) among B19 co-infected CHB patients were significantly higher than serum ALT levels (Median 43.0, IQR 33.0-61.5 IU/L) (p=0.023) and serum AST levels (Median 31 (26.50-53.00) IU/L) (p=0.013) in CHB mono-infected patients However the difference in serum bilirubin levels was not significant amongst the two groups (p=0.25). No aggravation of liver dysfunction was seen in B19 co-infected CHC patients.
Interpretation and conclusions: Parvovirus B19 is prevalent equally amongst HBV, HCV infected and healthy population. Co-infection of B19 with HCV did not increase the frequency of liver dysfunction but it definitely aggravates the liver dysfunction in CHB co-infected patients.
Chorba T, Coccia P, Holman RC, Tattersall P, Anderson LJ, Sudman J et al. The role of parvovirus B19 in aplastic crisis and erythema infectiosum (fifth disease). J Infect Dis. 1986;154:383- 93.
Young NS, Brown KE. Parvovirus B19. N Engl J Med.2004; 350:586-97.
Gallinella G, Zuffi E, Gentilomi G, Manaresi E, Venturoli S, Bonvicini F et al. Relevance of B19 markers in serum samples for a diagnosis of parvovirus B19-correlated diseases. J Med Virol. 2003;71:135-9.
Wang C, Heim A, Schlaphoff V, Suneetha PV, Stegmann KA, Jiang H et al. Intrahepatic long term persistence of parvovirus B19 and its role in chronic viral hepatitis. J Med Virol. 2009;81: 2079-88.
Krygier S, Steinbrecher UP, Petric M, Erb SR, Chung SW, Scudamore CH et al. Parvovirus B19 induced hepatic failure in an adult requiring liver transplantation. World J Gastroenterol. 2009;15:4067-69.
Kim BJ, Yoo KH, Li K, Kim MN. Parvovirus B19 infection associated with acute hepatitis in infant. Pediatr Infect Dis J.2009;28:667.
Toan NL, Song LH, Kremsner PG, Duy DN, Binh VQ, Duechting A et al. Co-infection of human parvovirus B19 in Vietnamese patients with hepatitis B virus infection. J Hepatol. 2006;45: 361-69.
Hsu TC, Chen TY, Lin MC, Tzang BS, Tsay GJ. Human parvovirus B19 infection in patients with chronic hepatitis B or hepatitis C infection. J Gastroenterol Hepatol. 2005;20:733-38.
Opaleye OO, Fagbami AH, Lalremruata A, Kun JF. Prevalence and association of human parvovirus B19V with hepatitis B and C viruses in Nigeria. J Med Virol. 2011;83:710-16.
Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004;11:97-107.
World Health Organisation. Global policy report on the prevention and control of viral hepatitis in WHO member states. 2013 July.
Chowdhury A. Epidemiology of hepatitis B virus infection in India. Hep B Annual. 2004;1:17-24.
Batham A, Narula D, Toteja T, Sreenivas V, Puliyel JM. Sytematic review and meta-analysis of prevalence of hepatitis B in India. Indian Pediatr. 2007;44:663-74.
Saravanan S, Velu V, Kumarasamy N, Shankar EM, Nandakumar S, Murugavel KG et al. The prevalence of hepatitis B virus and hepatitis C virus infection among patients with chronic liver disease in South India. Int J Infect Dis. 2008;12:513-18.
Arora D, Jindal N, Dang R, Kumar R. Rising sero-prevalence of HCV a silent killer: emerging problem. Int J Pharm Pharm Sci. 2011;3:57-59.
Sharad S, Kapur S. Emerging Human Infections: An Overview on Parvovirus B19. Journal, Indian Academy of Clinical Medicine. 2005;6:319-26.
Kumar S, Gupta RM, Sen S et al. Seroprevalence of human parvovirus B19 in healthy blood donors. Med J Armed Forces India. 2013;69:268-72.
Pongratz G, Lindner J, Modrow S, Schimanski S, Scholmerich J, Fleck M. Persistent parvovirus B19 infection detected by specific CD4+ T-cell responses in a patient with hepatitis and polyarthritis. J Intern Med. 2009;266:296-301.
Yu X, Wang J, Zhao B, Ghildyal R. PARV-4 coinfection is associated with disease progression in HBV patients in Shanghai. J. Med. Diagn Meth. 2015;4:168.